Since KRAS mutational status has been previously reported as a strong biomarker of response in this cohort [10], we sequenced mRNA for a subset of 76 patients and investigated differences in the transcriptomic profile of KRAS‐mt and KRAS‐wt tumors in order to gain insights into the mechanisms by which KRAS mutations increase tumor aggressiveness. The gene discussed is KRAS; the disease is neoplasm.